

35 U.S.C. §112, First Paragraph

Claims 18, 19, 21 and 47-53 stand rejected under 35 U.S.C. §112, first paragraph, as not described in the specification in such a way as to enable one skilled in the art to make or use the invention. Specifically, the Examiner maintains that one skilled in the art would have to resort to undue trial and error experimentation to perform the claimed method of identifying Rad51 mutations associated with disease. Applicants respectfully disagree.

The Examiner has characterized the pending claims as having utility only as a method of identifying Rad51 mutations for diagnosis of disease. While diagnosis of disease is one possible utility for the instant invention, it is not, as the Examiner asserts, the only utility. The instant invention may be used in the development of drugs, e.g. recombinant p53 proteins or recombinant BRCA1 proteins, which interact with the Rad51 protein, where mutations to Rad51 sequence may be integral to the drug's function. Furthermore, there is no "disease diagnosis" limitation recited in Claims 18, 19, 21, 51, and 52. These Claims are directed to methods of comparing the Rad51 sequence of a mammalian cell or human individual with that of a wild type Rad51 sequence to determine whether the Rad51 sequence has a mutation, and wherein the mutation effects known Rad51 activities. Accordingly, insofar as the Examiner's arguments contained in the April 22, 2002 Office Action are all directed to a lack of disclosure relating mutations in Rad51 sequence with disease, those arguments are not germane to a rejection of Claims 18-19, 21, and 51-52 and withdrawal of the rejection on those grounds is respectfully requested.

As to the remaining claims, Claims 47-50 and 53, which do relate to a method of identifying a mammalian cell containing a mutant Rad51 gene indicative of a disease state or propensity for a disease state, the Applicants submit that undue experimentation would not be necessary to practice the claimed invention. The Examiner bases his assertion that undue experimentation would be needed to practice the invention on his conclusion that no guidance is provided in the specification for the identification of a mutant Rad51 gene that is associated with a disease, however such guidance is indeed provided.

As evidence that the specification is enabled for methods of identifying mutant Rad51 genes by comparing all or part of an endogenous Rad51 gene to a known Rad51 gene wherein a difference in the sequence is indicative of a disease state or a propensity for a disease state, Applicants draw the Examiner's attention to a recent article which describes a single nucleotide mutation in the Rad51 gene that increases cancer risk for BRCA2 carriers. See Levy-Lahad *et al.*, PNAS, 98:3232-3236 (2001), enclosed herein. This publication is presented to show that the utility asserted and shown in the application is supported by subsequent work by a third party. Accordingly, the specification fully enables the method of identifying mutant Rad51 sequences wherein the mutation is indicative of a disease state or a propensity for a disease state. See In re Wilson, 135 USPQ 442, 444 (CCPA 1962); Ex parte Obukowicz, 27 USPQ 2d 1063 (BPAI 1993); Gould v. Quigg, 3 USPQ 2d 1302,1305 (Fed. Cir. 1987):

“it is true that a later dated publication cannot supplement an insufficient disclosure in a prior dated application to render it enabling. In this case the later dated publication was not offered as evidence for this purpose. Rather, it was offered . . . as evidence that the disclosed device would have been operative.”

Levy-Lahad *et al.* report the presence of a mutation in the 5' untranslated region of the Rad51 gene results in a four-fold increase in breast cancer risk for BRCA2 carriers. Levy-Lahad *et al.* made use of techniques (nucleic acid extraction, nucleic acid sequencing, nucleic acid digestion by restriction enzymes and statistical analysis) which were available to one of skill in the art at the time of filing of the instant application. Furthermore, the disease state studied in Levy-Lahad *et al.*, breast cancer, is specifically recited in the specification on page 10, line 3, as one which would be amenable to evaluation by the instant application. Accordingly, Applicants respectfully request withdrawal of the rejection of Claims 47-50 and 53 under 35 U.S.C. § 112, first paragraph.


Conclusion

On the basis of the remarks presented herein, Applicants believe that this application is now in condition for immediate allowance. Applicants respectfully request that the Examiner

pass this application to issue, and early notice of such is requested. This paper is filed under 37 C.F.R. section 1.34(a).

Respectfully submitted,
DORSEY & WHITNEY LLP

Date: 5/21/03



Richard F. Trecartin
Reg. No. 31,801

Four Embarcadero Center, Suite 3400
San Francisco, California 94111-4187
Telephone: (415) 781-1989

A single nucleotide polymorphism in the *RAD51* gene modifies cancer risk in *BRCA2* but not *BRCA1* carriers

E. Levy-Lahad^{*†}, A. Lahad[‡], S. Eisenberg^{*}, E. Dagan[§], T. Paperna[§], L. Kasinetz[§], R. Catane[¶], B. Kaufman[¶], U. Beller[¶], P. Renbaum^{*}, and R. Gershoni-Baruch[§]

^{*}Medical Genetics Unit, Shaare Zedek Medical Center and Hebrew University/Hadassah Medical School, P.O. Box 3235, Jerusalem 91031, Israel; [†]Department of Family Medicine, Hebrew University/Hadassah Medical School, P.O. Box 12272, Jerusalem 91120, Israel; [‡]Genetics Institute, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel; and [¶]Institute of Oncology and Gynecologic Oncology Unit, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Israel

Communicated by Arno G. Motulsky, University of Washington, Seattle, WA, December 28, 2000 (received for review November 3, 2000)

BRCA1 and *BRCA2* carriers are at increased risk for both breast and ovarian cancer, but estimates of lifetime risk vary widely, suggesting their penetrance is modified by other genetic and/or environmental factors. The *BRCA1* and *BRCA2* proteins function in DNA repair in conjunction with *RAD51*. A preliminary report suggested that a single nucleotide polymorphism in the 5' untranslated region of *RAD51* (135C/G) increases breast cancer risk in *BRCA1* and *BRCA2* carriers. To investigate this effect we studied 257 female Ashkenazi Jewish carriers of one of the common *BRCA1* (185delAG, 5382insC) or *BRCA2* (6174delT) mutations. Of this group, 164 were affected with breast and/or ovarian cancer and 93 were unaffected. *RAD51* genotyping was performed on all subjects. Among *BRCA1* carriers, *RAD51*-135C frequency was similar in healthy and affected women [6.1% (3 of 49) and 9.9% (12 of 121), respectively], and *RAD51*-135C did not influence age of cancer diagnosis [Hazard ratio (HR) = 1.18 for disease in *RAD51*-135C heterozygotes, not significant]. However, in *BRCA2* carriers, *RAD51*-135C heterozygote frequency in affected women was 17.4% (8 of 46) compared with 4.9% (2 of 41) in unaffected women ($P = 0.07$). Survival analysis in *BRCA2* carriers showed *RAD51*-135C increased risk of breast and/or ovarian cancer with an HR of 4.0 [95% confidence interval 1.6–9.8, $P = 0.003$]. This effect was largely due to increased breast cancer risk with an HR of 3.46 (95% confidence interval 1.3–9.2, $P = 0.01$) for breast cancer in *BRCA2* carriers who were *RAD51*-135C heterozygotes. *RAD51* status did not affect ovarian cancer risk. These results show *RAD51*-135C is a clinically significant modifier of *BRCA2* penetrance, specifically in raising breast cancer risk at younger ages.

Germ-line mutations in the *BRCA1* and *BRCA2* genes increase susceptibility for both breast and ovarian cancer. Penetrance of these mutations is incomplete and age-dependent, thus cancer risk in carriers continues to increase with age even though the mean age of cancer diagnosis is younger in *BRCA1*/*BRCA2* carriers compared with noncarriers (1). Estimates of penetrance have varied widely, perhaps as a result of different ascertainment schemes and/or allelic effects. In families ascertained for multiple affected individuals suitable for linkage analysis, lifetime cancer risk (by age 70) was 85% for breast cancer in both *BRCA1* and *BRCA2* carriers (2, 3), 63% for ovarian cancer in *BRCA1* carriers (2), and 27% for ovarian cancer in *BRCA2* carriers (3). Significantly lower risk estimates were obtained in studies performed in less selected families or at the population level, with a 36–56% lifetime risk for breast cancer (4–7) and a 16% lifetime risk for ovarian cancer (5). These studies were performed in specific ethnic groups (Ashkenazi Jewish and the Iceland population) that harbor a limited number of specific mutations and could therefore be representative of these alleles, rather than reflect the general penetrance of *BRCA1*/*BRCA2* mutations. Such differences suggest that penetrance of *BRCA1*/*BRCA2* mutations is modified by other

genetic and/or environmental factors. Identification of such modifiers has important implications, e.g., in facilitating more accurate risk assessment in carriers who face difficult clinical choices regarding prophylactic mastectomy and oophorectomy.

Candidate modifiers include genes whose products are known to interact with *BRCA1* and *BRCA2* (reviewed in ref. 8). *RAD51* is a homologue of bacterial RecA, which is required for meiotic and mitotic recombination and for recombinational repair of double-strand DNA breaks. Both *BRCA1* and *BRCA2* have been shown to interact with *RAD51* (9–11), and the phenotype of murine *Brcal*- and *Brc2*-knockout mice is similar to that of *Rad51* knockouts (reviewed in ref. 8). A missense mutation in *RAD51* (Arg-150-Glu) has been described in two Japanese patients with bilateral breast cancer (12), and Wang *et al.* orally presented evidence that a single nucleotide polymorphism (SNP) in the 5' untranslated region (UTR) of *RAD51* is associated with increased breast cancer risk in *BRCA1* and *BRCA2* carriers but does not influence breast cancer risk in women who are not *BRCA1*/*BRCA2* carriers. This SNP, designated 135 g/c, is a substitution of G for C at position 135 of the human *RAD51* cDNA (GenBank accession no. D14134). The aim of the present study was to investigate further the association between the *RAD51* 5' UTR polymorphism and disease status in *BRCA1* and *BRCA2* carriers and to determine whether the *RAD51*-135C polymorphism is indeed a modifier of *BRCA1* and/or *BRCA2* penetrance.

Methods

Subjects and Clinical Data. Participants included all 289 female Ashkenazi Jewish carriers, both healthy and affected, ascertained through Cancer Genetics clinics at two institutions in Israel: Shaare Zedek Medical Center (SZMC) in Jerusalem and Rambam Medical Center (RMC) in Haifa. Nineteen carriers at SZMC were identified through an ongoing study of all Ashkenazi Jewish women diagnosed with breast or ovarian cancer at SZMC since January 1995. All other carriers were identified through patients counseled for family history of breast and/or ovarian cancer history. Clinical data collected on each subject included type of malignancy (based on pathology reports), age at diagnosis or at last follow-up exam, and age at prophylactic surgery if any was performed. All women received genetic counseling and gave informed consent for genetic testing. The study was approved by the institutional review boards (Helsinki commit-

Abbreviations: HR, Hazard ratio; NS, not significant; CI, confidence interval.

[†]To whom reprint requests should be addressed. E-mail: lahad@szmc.org.il.

Wang, W., Tucker, M. A., Doody, M. M., Tarone, R. E. & Struewing, J. P. (1999) *Am. J. Hum. Genet.* 65: 22 (abstr.).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Table 1. *RAD51-135C* frequency in *BRCA1* and *BRCA2* mutation carriers

Disease status	<i>BRCA1</i> carriers		<i>BRCA2</i> carriers	
	<i>RAD51-135C</i> frequency	Mean age*, SD	<i>RAD51-135C</i> frequency**	Mean age*, SD
Healthy	3/49 (6.1%)	47.8 (13.5)	2/41 (4.9%)	45.6 (10.7)
Total affected	12/121 (9.9%)	44.9 (10.3)	8/46 (17.4%)	49.9 (10.9)
Unilateral breast cancer	6/64 (9.4%)	43.0 (10.6)	5/28 (17.9%)	46.0 (9.2)
Bilateral breast cancer	0/14 (0%)	41.9 (7.8)	1/5 (20%)	45.6 (10.4)
Breast & ovarian cancer	3/13 (23%)	50.4 (7.4)	1/1 (100%)	62
Ovarian cancer	3/30 (10%)	48.0 (10.6)	1/12 (8.3%)	61.2 (7.3)

*Mean age was not significantly different between affected and unaffected *BRCA1* carriers. In *BRCA2* carriers, $P = 0.07$.

**In *BRCA2* carriers $\chi^2 = 11.1$ for *RAD51-135C* frequency and disease status (4 df), $P = 0.03$. For *RAD51-135C* frequency in healthy vs. affected carriers, $P = 0.07$.

tees) at both SZMC and RMC. Samples from healthy Ashkenazi controls (SZMC) were anonymous DNA samples from unrelated healthy persons who reported all four grandparents as being Ashkenazi Jewish and who gave their consent for anonymous testing.

Molecular Analysis. DNA extraction. Genomic DNA was extracted from peripheral blood samples by using standard high-salt extraction (13).

Analysis of *BRCA1* and *BRCA2* mutations. Genomic DNA was analyzed for the three founder mutations common in Ashkenazi Jews (*BRCA1-185delAG*, *5382insC*, and *BRCA2-6174delT*) by using previously published methods (4, 14).

***RAD51* genotyping.** *RAD51* genotyping was performed by PCR amplification of a 157-bp region around nucleotide 135. This amplicon contains a single *MvaI* site that is abolished by the 135C polymorphism. Wild-type alleles are digested by *MvaI* resulting in 86- and 71-bp products. The 135C allele is not digested by *MvaI*, resulting in a single 157-bp product. PCR was performed by using the following primers: *RAD51AF* (5'-TGGGAAC-TGCAACTCATCTGG-3') and *RAD51RR* (5'-GCGCTC-CTCTCTCCAGCAG-3') at a final Mg concentration of 1.5 mM and an annealing temperature of 53°C. After digestion with *MvaI* (Fermentas, Vilnius, Lithuania) for 4 h at 37°C, samples were run on a 3% agarose gel. Direct sequencing of the *RAD51* amplicon (ABI prism 377, Perkin-Elmer) was performed on three samples heterozygous for the *MvaI* site, confirming the accuracy of the restriction-digest assay in identifying the *RAD51-135C* polymorphism.

Statistical Analysis. *RAD51* allele frequencies in affected vs. unaffected subjects were compared by using the χ^2 test. The association of disease status in *BRCA1/BRCA2* carriers and *RAD51-135C* was analyzed by using logistic regression, and analysis of disease-free survival was done by using Cox proportional hazard. Several outcomes were analyzed—breast and/or ovarian cancer, breast cancer only, and ovarian cancer only. In all analyses, healthy carriers were censored at the age of last follow-up exam or at the age of the relevant prophylactic surgery (i.e., prophylactic oophorectomy for ovarian cancer and prophylactic mastectomy for breast cancer). Outcomes in affected women were treated as follows: (i) for analysis of breast and/or ovarian cancer, outcome in affected women was the age at diagnosis of the first malignancy; (ii) for analysis of breast cancer only, the outcome in women affected with breast cancer was the age of breast cancer diagnosis; women with ovarian cancer were censored at the age of prophylactic mastectomy, last follow-up exam, or death (whichever came first); and (iii) for analysis of ovarian cancer only, the outcome in women affected with ovarian cancer was the age of ovarian cancer diagnosis, and women with

breast cancer were censored at age of prophylactic oophorectomy, last follow-up exam, or death (whichever came first).

Results

There are 289 *BRCA1* and *BRCA2* carriers currently followed at both participating institutions. *RAD51* mutation analysis could not be performed in 25 cases, and the age at diagnosis was not known in three cases, leaving a total of 261 subjects in which complete clinical data and genetic analyses were available. Two subjects were excluded because they were affected with cancers other than breast or ovarian (one with colorectal cancer and one with lymphoma). Two additional subjects were excluded because they were double heterozygotes (*BRCA1-185delAG* and *BRCA2-6174delT*) and could not be assigned a single mutation status. Analysis therefore was performed on 257 carriers who are members of 205 unrelated families (141 segregating *BRCA1* mutations and 64 segregating *BRCA2* mutations).

Among all carriers, 93 were unaffected, and 164 were affected with breast and/or ovarian cancer. Of 170 *BRCA1* carriers, 49 (29%) were unaffected, and of 87 *BRCA2* carriers, 41 (47%) were unaffected. Mean age at diagnosis in affected carriers and mean age at last follow-up exam in healthy carriers were not significantly different (Table 1). No *RAD51-135C* homozygotes were identified among all carriers or among 73 healthy Ashkenazi controls. *RAD51-135C* heterozygote frequency among all healthy carriers was 5.5% (5 of 90) compared with 12% (20 of 167) among affected carriers. This difference was not significant (Table 1). In *BRCA2* carriers, there was a trend to higher frequency of *RAD51-135C* among affected carriers ($P = 0.07$). *RAD51-135C* heterozygote frequency in 73 healthy Ashkenazi controls was 8.2% (6 of 73), intermediate between the frequencies observed in affected and unaffected *BRCA1/BRCA2* carriers.

Initial analysis was performed only for unrelated cases. Results were similar to those presented below for all cases, but power was obviously lower because of the smaller sample size. Except for one mother/daughter pair, both of which were *BRCA1* carriers and *RAD51-135C* heterozygotes, all other *RAD51-135C* heterozygotes were unrelated to each other. Furthermore, *RAD51*, *BRCA1*, and *BRCA2* are located on different chromosomes and segregate independently, and thus information gained from multiple members of the same family is pertinent to the question of genetic interaction between *BRCA1/BRCA2* and *RAD51*. Results therefore are presented for all cases (257 carriers from 205 families). We first analyzed the effect of *RAD51-135C* on diagnosis of any related malignancy (breast and/or ovarian cancer) in all carriers (*BRCA1* and *BRCA2* combined). *RAD51* status did not influence total malignancy risk [Hazard ratio (HR) = 1.46 for *RAD51-135C* vs. normal homozygotes, not significant (NS)]. However, as a covariate, the specific *BRCA* gene was a significant predictor of disease risk [HR = 0.6,




Fig. 1. Cancer risk in *BRCA1* carriers—survival analysis according to *RAD51* genotype. *RAD51-135C* +—heterozygotes for the *RAD51-135C* polymorphism. *RAD51-135wt* (wild type)—homozygous normal (GG) at nucleotide 135. (A) Fraction of *BRCA1* carriers remaining free of both breast and ovarian cancer. For *RAD51-135C* heterozygotes, HR = 1.18 (NS). (B) Fraction of *BRCA1* carriers remaining free of breast cancer. For *RAD51-135C* heterozygotes, HR = 1.16 (NS). (C) Fraction of *BRCA1* carriers remaining free of ovarian cancer. For *RAD51-135C* heterozygotes, HR = 1.28 (NS).

P = 0.01 for *BRCA2* vs. *BRCA1*], and thus further analyses were performed separately for *BRCA1* and *BRCA2* carriers. This separate analysis is justified also on the grounds that any gene–gene interaction would not necessarily be similar for both *BRCA1* and *BRCA2*.

In *BRCA1* carriers, *RAD51-135C* was not found to influence disease risk (Fig. 1). This lack of effect was true for both breast and ovarian cancer combined (HR = 1.18, NS; Fig. 1A), breast cancer only (HR = 1.16, NS; Fig. 1B), and ovarian cancer only (HR = 1.28, NS; Fig. 1C). However in *BRCA2* carriers, *RAD51-135C* significantly increased cancer risk (Fig. 2). For both breast and ovarian cancer combined, the HR for *BRCA2* carriers who were also *RAD51-135C* heterozygotes was 4.0 (95% CI 1.6–9.8, *P* = 0.003; Fig. 2A). As noted above, information gained from multiple family members is relevant to genetic interaction between independently segregating loci. However, if a substantial proportion of *RAD51-135C* heterozygotes among *BRCA2* carriers were related closely, other unidentified familial factors could have confounded the observed *RAD51-BRCA2* interaction. To exclude this possible bias rigorously (even though all *RAD51-135C* heterozygotes among *BRCA2* carriers were unrelated), analysis in *BRCA2* carriers was performed also by using only unrelated subjects. In unrelated *BRCA2* carriers, for both breast and ovarian cancer combined, the HR for *RAD51-135C* heterozygotes was 3.5 (95% CI 1.4–8.9, *P* = 0.008). Notably, all *BRCA2/RAD51-135C* carriers became affected by age 58, whereas among *BRCA2* carriers who were not *RAD51-135C* heterozygotes, 50.4% remained unaffected at the same age.

To explore the *RAD51-BRCA2* interaction further, it also was tested for breast and ovarian cancer as separate outcomes. *RAD51-135C* did not influence ovarian cancer risk in *BRCA2* carriers [HR = 1.23 (NS), *P* = 0.85 for *RAD51-135C* heterozygotes vs. normal homozygotes], but the number of ovarian cancer outcomes in *BRCA2* carriers was small (Fig. 2C). Breast cancer risk, however, was elevated significantly in *BRCA2* carriers who were also *RAD51-135C* heterozygotes with an HR of 3.46 (95% CI 1.3–9.2, *P* = 0.01; Fig. 2B). Thus, most of the elevated cancer risk associated with the *RAD51-135C* polymorphism in *BRCA2* carriers is explained by an increase in breast cancer risk. Similar results were obtained with analysis by logistic regression, in which the outcome is dichotomous (presence or absence of breast cancer diagnosis, regardless of age at diagnosis). In *BRCA1* carriers, breast cancer risk was not elevated significantly in *RAD51-135C* heterozygotes (odds ratio = 1.1, NS), but in *BRCA2* carriers, the odds ratio for breast cancer in *RAD51-135C* heterozygotes was 4.3 (*P* = 0.046). Notably, the magnitude of the *RAD51-135C* effect found by logistic regression was similar to that found with survival analysis by using Cox proportional hazard. The level of significance is lower because of reduced power when information from age at diagnosis is not taken into account.

Discussion

We observed that in *BRCA2-6174delT* carriers, presence of the *RAD51-135C* allele results in an approximately 4-fold increase in breast cancer risk (Fig. 2). This elevated risk was observed consistently by using different analyses (Cox proportional hazard and logistic regression) and in independent unrelated cases as well as in the entire study group. *RAD51-135C* did not influence breast or ovarian cancer risk in *BRCA1-185delAG/5382insC* carriers (Fig. 1). Because both genetic and environmental modifiers are more likely to influence low-penetrance mutations than high-penetrance mutations, these results are consistent with previous observations of lower penetrance of *BRCA2* and more specifically the *BRCA2-6174delT* mutation. As noted above, studies in high-risk families found ovarian cancer risk is lower in *BRCA2* carriers compared with *BRCA1* carriers (3), and despite similar life-




Fig. 2. Cancer risk in *BRCA2* carriers—survival analysis according to *RAD51* genotype. *RAD51-135C* + -heterozygotes for the 135C polymorphism. *RAD51-135wt* (wild type) – homozygous normal (GG) at nucleotide 135. (A) Fraction of *BRCA2* carriers remaining free of both breast and ovarian cancer. For *RAD51-135C* heterozygotes, HR = 4.0 [95% confidence interval (CI) 1.6–9.8, $P = 0.003$]. (B) Fraction of *BRCA2* carriers remaining free of breast cancer. For *RAD51-135C* heterozygotes, HR = 3.46 (95% CI 1.3–9.2, $P = 0.01$). All *BRCA2* carriers who also were *RAD51-135C* heterozygotes became affected by age 58, whereas 50.4% of those who were *RAD51-135C* normal homozygotes remained unaffected at the same age. (C) Fraction of *BRCA2* carriers remaining free of ovarian cancer. For *RAD51-135C* heterozygotes, HR = 1.23 (NS).

time breast cancer risk, a large study found a suggestion of lower risk in *BRCA2* carriers under 50 years of age (3). In Ashkenazi Jews, there is evidence that the *BRCA2-6174delT* mutation may be associated with lower cancer risk than the *BRCA1* mutations common in this population (*185delAG* and *5382insC*). *BRCA2-6174delT* is the most common mutation at the population level, with an estimated carrier frequency of 1.4%, compared with 1.1% for both *BRCA1* mutations combined (15). However, among affected carriers, the frequency of *BRCA2* mutations is approximately half that of *BRCA1* mutations, suggesting that many *BRCA2* carriers remain unaffected (ref. 15; Table 2). In this study, in which families were ascertained mostly on the basis of moderate family history (the mean number of affected relatives, excluding the proband, was 1.8), the *BRCA2-6174delT* mutation was approximately half as frequent as the *BRCA1-185delAG* and *5382insC* mutations combined.

The biological effect of the *RAD51-135C* polymorphism is yet to be elucidated and will be important to investigate. It is located in the 5' untranslated region of the *RAD51* gene and theoretically could affect mRNA stability and/or translation efficiency, leading to altered *RAD51* protein levels. Altered *RAD51* levels could influence the activity of the multiprotein DNA-repair complex that includes *BRCA1*, *BRCA2*, and *RAD51*. Indeed, recent studies suggest altered *RAD51* expression may play a role in breast cancer pathogenesis. In breast carcinomas, loss of heterozygosity at the *RAD51* locus has been reported in 32% (41 of 127) (16), and reduced Rad51 protein levels have been found in 30% (54 of 179) (17). However, histological grading of sporadic invasive ductal carcinoma has been correlated with overexpression of wild-type Rad51 (18). In one case report, a missense mutation in *RAD51* (Arg-150-Glu) has been associated with bilateral breast cancer in two Japanese patients (12), although it is unknown whether this mutation segregated with the disease in their families and whether they were also carriers of *BRCA1* or *BRCA2* mutations. In our study, *RAD51-135C* was not associated specifically with bilaterality of breast cancer, although this result could be due to the small number of bilateral breast cancer cases. Among *BRCA2* carriers, the frequency of *RAD51-135C* heterozygotes in women with bilateral breast cancer was 1 in 5 (20%), similar to 17.9% (5 in 28) in unilateral cases (Table 1). Among *BRCA1* carriers, none of the 14 women with bilateral breast cancer were *RAD51-135C* heterozygotes, compared with 9.4% (6 of 64) of those with unilateral breast cancer.

The differential effect of *RAD135C* on *BRCA2* vs. *BRCA1* may be related to the different pathways in which the BRCA proteins play a role. Although both *BRCA1* and *BRCA2* are involved in DNA double-strand break repair by means of homologous recombination (a process requiring *RAD51*), modulation of *RAD51* may not be as crucial for *BRCA1* compared with *BRCA2*-mediated repair (reviewed in ref. 19). Conversely, as suggested by the observation that some *BRCA1* mutations are more severe than *BRCA2* mutations, DNA repair may be so impaired in the presence of *BRCA1* defects that more minor alterations in *RAD51* have no detectable impact. Our results also raise the possibility that *RAD51-135C* may have a differential effect on breast vs. ovarian cancer risk. The lack of effect on ovarian cancer could be the result of the small number of ovarian cancer outcomes in *BRCA2* carriers in this study. However, if it is confirmed in a larger series, it may be explained by differences in downstream targets in breast compared with ovarian tissues.

Current breast cancer prevention strategies in *BRCA2* carriers include chemoprevention with tamoxifen, prophylactic mastectomy, and probably prophylactic oophorectomy (20–22). Tamoxifen is expected to reduce breast cancer risk by up to 49%,

Table 2. Relative frequency of the common *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish subjects and families affected with breast/ovarian cancer

Study subjects	Number	Affected <i>BRCA1</i> carriers, %	Affected <i>BRCA2</i> carriers, %	Ref.
Unselected living breast cancer cases	412	34 (8.3%)	15 (3.6%)	23
Unselected breast cancer cases, pathology slides	268	10 (3.7%)	8 (3%)	6
Unselected ovarian cancer cases	208	57 (27%)	29 (14%)	24
Selected breast cancer cases	178	16 (9%)	8 (4.5%)	25
Breast and breast/ovarian families	220	91 (41%)	9 (4%)	26
Families with known <i>BRCA1</i> / <i>BRCA2</i> mutations	205	141 (69%)	64 (31%)	This study
Breast or ovarian cancer survivors among Jewish volunteers	302	16 (5.3%)	11 (3.6%)	5

although its efficacy has not been demonstrated specifically in *BRCA1* or *BRCA2* carriers (20). Prophylactic mastectomy is effective in reducing breast cancer incidence by 90%, but this reduction is counterbalanced by the psychological impact of such surgery and the large number of mastectomies probably needed for each life saved (21). If the association of *RAD51-135C* with breast cancer risk in *BRCA2* carriers is confirmed in additional studies, *RAD51* status may be useful in differentiating those

carriers most likely to benefit from aggressive prevention measures from those in whom more conservative management would be appropriate.

We thank Ms. Gaya Chicco for excellent technical assistance. This study was supported in part by a project grant from the Israel Cancer Research Fund (to E.L.L. and R.C.) and a gift from the Basker family, in loving memory of Eileen Basker.

1. Brody, L. C. & Biesecker, B. B. (1998) *Medicine (Baltimore)* **77**, 208–226.
2. Easton, D. F., Ford, D. & Bishop, D. T. (1995) *Am. J. Hum. Genet.* **56**, 265–271.
3. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) *Am. J. Hum. Genet.* **62**, 676–689.
4. Levy-Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M., Weber, B. L., Beller, U., Lahad, A. & Halle, D. (1997) *Am. J. Hum. Genet.* **60**, 1059–1067.
5. Strucwing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C. & Tucker, M. A. (1997) *N. Engl. J. Med.* **336**, 1401–1408.
6. Fodor, F. H., Weston, A., Bleiweiss, I. J., McCurdy, L. D., Walsh, M. M., Tartter, P. I., Brower, S. T. & Eng, C. M. (1998) *Am. J. Hum. Genet.* **63**, 45–51.
7. Thorlacius, S., Strucwing, J., Hartge, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., Wacholder, S., Tulinius, H. & Eyfjord, J. E. (1998) *Lancet* **352**, 1337–1339.
8. Welcsh, P. L., Owens, K. N. & King, M. C. (2000) *Trends Genet.* **16**, 69–74.
9. Wong, A. K. C., Pero, R., Ormonde, P. A., Tavtigian, S. V. & Bartel, P. L. (1997) *J. Biol. Chem.* **272**, 31941–31943.
10. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T. & Livingston, D. M. (1997) *Cell* **88**, 265–275.
11. Chen, P. L., Chen, C. F., Chen, Y., Xiao, J., Sharp, Z. D. & Lee, W. H. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 5287–5292.
12. Kato, M., Yano, K., Matsuo, F., Saito, H., Katagiri, T., Kurumizaka, H., Yoshimoto, M., Kasumi, F., Akiyama, F., Sakamoto, G., et al. (2000) *J. Hum. Genet.* **45**, 133–137.
13. Miller, S. A., Dykes, D. D. & Polesky, H. F. (1988) *Nucleic Acids Res.* **16**, 1215.
14. Gershoni-Baruch, R., Dagan, E., Fried, G., Kepten, I. & Robinson, E. (1999) *Eur. J. Hum. Genet.* **7**, 833–836.
15. Roa, B. B., Boyd, A. A., Volcik, K. & Richards, C. S. (1996) *Nat. Genet.* **14**, 185–187.
16. Gonzalez, R., Silva, J. M., Dominguez, G., Garcia, J. M., Martinez, G., Vargas, J., Provencio, M., Espana, P. & Bonilla, F. (1999) *Br. J. Cancer* **81**, 503–509.
17. Yoshikawa, K., Ogawa, T., Baer, R., Hemmi, H., Honda, K., Yamauchi, A., Inamoto, T., Ko, K., Yazumi, S., Motoda, H., et al. (2000) *Int. J. Cancer* **88**, 28–36.
18. Maacke, H., Opitz, S., Jost, K., Hamdorf, W., Henning, W., Kruger, S., Feller, A. C., Lopens, A., Diedrich, K., Schwinger, E. & Sturzbecher, H. W. (2000) *Int. J. Cancer* **88**, 907–913.
19. Karan, P. (2000) *Curr. Opin. Genet. Dev.* **10**, 144–150.
20. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) *J. Natl. Cancer Inst.* **90**, 1371–1388.
21. Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) *N. Engl. J. Med.* **340**, 77–84.
22. Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) *J. Natl. Cancer Inst.* **91**, 1475–1479.
23. Warner, E., Foulkes, W., Goodwin, P., Meschino, W., Blondal, J., Paterson, C., Ozcelik, H., Goss, P., Allingham-Hawkins, D., Hamel, N., et al. (1999) *J. Natl. Cancer Inst.* **91**, 1241–1247.
24. Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., et al. (2000) *Am. J. Hum. Genet.* **66**, 1259–1272.
25. Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N. & Peretz, T. (1997) *Am. J. Hum. Genet.* **60**, 505–514.
26. Tonin, P., Weber, B., Offit, K., Couch, F., Rebbeck, T. R., Neuhausen, S., Godwin, A. K., Daly, M., Wagner-Costalos, J., Berman, D., et al. (1996) *Nat. Med.* **1179–1183**.